Is Roivant Sciences Ltd. (ROIV) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.5% / 30% | 23.7% / 30% | 0.0% / 30% | 889.32% / 5% | ✗ NOT HALAL |
| DJIM | 0.5% / 33% | 23.7% / 33% | 0.0% / 33% | 889.32% / 5% | ✗ NOT HALAL |
| MSCI | 1.8% / 33% | 89.9% / 33% | 0.0% / 33% | 889.32% / 5% | ✗ NOT HALAL |
| S&P | 0.5% / 33% | 23.7% / 33% | 0.0% / 33% | 889.32% / 5% | ✗ NOT HALAL |
| FTSE | 1.8% / 33% | 89.9% / 33% | 0.0% / 50% | 889.32% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -16965.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -19.1% | |
| Return on Assets (ROA) | -14.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$839M |
| Free Cash Flow | -$844M |
| Total Debt | $100M |
| Debt-to-Equity | 2.2 |
| Current Ratio | 30.7 |
| Total Assets | $5.4B |
Price & Trading
| Last Close | $27.35 |
| 50-Day MA | $26.26 |
| 200-Day MA | $18.58 |
| Avg Volume | 6.5M |
| Beta | 1.2 |
|
52-Week Range
$8.73
| |
About Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Roivant Sciences Ltd. (ROIV) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Roivant Sciences Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Roivant Sciences Ltd.'s debt ratio?
Roivant Sciences Ltd.'s debt ratio is 0.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.8%.
What are Roivant Sciences Ltd.'s key financial metrics?
Roivant Sciences Ltd. has a market capitalization of $19.0B, and revenue of $29M. Return on equity stands at -19.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.